Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases.
The introduction of anti-tumor necrosis factor (TNF) therapies has dramatically improved the treatment of immune-mediated inflammatory diseases and provides treatment options for patients who do not respond to conventional disease-modifying antirheumatic drugs. However, the use of anti-TNF therapies still needs to be optimized. Dropoff rates, patients' lack of response, and toxicity are issues that need to be addressed to render these therapies more effective for more patients.
Bressler
Brian
B
Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
Haraoui
Boulos
B
Keystone
Edward
E
Sette
Alessandro
A
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D057915:Drug Substitution; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism; D055118:Medication Adherence; D018579:Patient Selection; D018570:Risk Assessment; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha